Cimzia and Cataract - a phase IV clinical study of FDA data

Summary:

Cataract is reported as a side effect among people who take Cimzia (certolizumab pegol), especially for people who are female, 60+ old, have been taking the drug for 1 - 6 months also take Enbrel, and have Diabetes.

The phase IV clinical study analyzes which people have Cataract when taking Cimzia. It is created by eHealthMe based on reports of 106,367 people who have side effects when taking Cimzia from the FDA, and is updated regularly.

What is Cimzia?

Cimzia has active ingredients of certolizumab pegol. It is often used in rheumatoid arthritis. eHealthMe is studying from 106,745 Cimzia users. Check the latest studies of Cimzia.

What is Cataract?

Cataract (clouding of the lens inside the eye) is found to be associated with 1,892 drugs and 2,133 conditions by eHealthMe. Check the latest studies of Cataract.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Aug, 07, 2026

106,367 people reported to have side effects when taking Cimzia.
Among them, 421 people (0.4%) have Cataract.

Among these 421 people:

* Approximation only. Some reports may have incomplete information.

Do you take Cimzia and have Cataract?

- Check whether Cataract is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Cimzia:

Cimzia (106,745 reports)

Cataract treatments and more:

Cataract (70,565 reports)

How severe was Cataract and when was it recovered:

Cataract in Cimzia

Expand to all the drugs that have ingredients of certolizumab pegol:

Cataract and drugs with ingredients of certolizumab pegol (653 reports)

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Cimzia:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Cataract:

Cataract (1,892 drugs)

Browse all the conditions that are associated with Cataract:

Cataract (2,133 conditions)

Related publications that referenced our studies

Lin SY, Lin CL, Ju SW, Wang IK, Lin CC, Lin CH, Hsu WH, Liang JA, "Increasing risk of cataract in HCV patients receiving anti-HCV therapy: A nationwide cohort study", PloS one, 2017 Mar .
Dsouza MC, "Could risperidone have caused the cataract?: A case report and review of literature", Journal of Research in Psychiatry and Behavioral Science, 2015 Jan .
Dsouza MC, "COULD RISPERIDONE HAVE CAUSED THE CATARACT", JRPBS, 2015 Jan .
Lin SY, Lin CL, Ju SW, Wang IK, Lin CC, Lin CH, Hsu WH, Liang JA, "Increasing risk of cataract in HCV patients receiving anti-HCV therapy: A nationwide cohort study", PloS one, 2017 Mar .
Dsouza MC, "Could risperidone have caused the cataract?: A case report and review of literature", Journal of Research in Psychiatry and Behavioral Science, 2015 Jan .
Dsouza MC, "COULD RISPERIDONE HAVE CAUSED THE CATARACT", JRPBS, 2015 Jan .

How the study uses the data?

The study uses data from the FDA. It is based on certolizumab pegol (the active ingredients of Cimzia) and Cimzia (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.